Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Ulz, P; Geigl, JB; Speicher, MR; Heitzer, E.
Latest technological developments in the analysis of circulating tumor DNA
MED GENET-BERLIN. 2016; 28(2): 234-244.
Doi: 10.1007/s11825-016-0089-z
[OPEN ACCESS]
Web of Science
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Heitzer Ellen
- Ulz Peter
- Co-Autor*innen der Med Uni Graz
- Geigl Jochen Bernd
- Speicher Michael
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The analysis of circulating tumor DNA (ctDNA) and circulating tumor cells, often known as liquid biopsy, is a rapidly developing field of medical research. Although it has taken decades since the discovery of cell-free DNA for it to be recognized as a suitable biomarker, the clinical benefit of ctDNA with regard to monitoring therapy response, the identification of resistance mechanisms, and novel emerging actionable targets, in addition to the detection of minimal residual disease, has recently been proven in numerous studies. Owing to the great variability of ctDNA in the circulation, together with the high degree of fragmentation, ctDNA is a challenging analyte. However, in recent years technological advances have contributed to a variety of routine applications of ctDNA analysis becoming a reality, given that a number of additional regulatory hurdles can be overcome.
- Find related publications in this database (Keywords)
- Liquid biopsies
- CtDNA analysis
- Biomarker
- Surrogate marker
- Clinical oncology
- Circulating tumor cells